Given recent advancements in blood-based Alzheimer’s disease biomarkers, a single blood sample provides the ability to assess multiple aspects of the Alzheimer’s disease pathological processes, namely amyloid-β, tau and neurodegeneration. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.